drugset / Trial / NCT01530620

Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity

NCT01530620

Phase 3 Completed 66 enrolled APOGEPHA Arzneimittel GmbH
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this clinical study is to compare efficacy and safety of propiverine hydrochloride extended and immediate release formulations in patients suffering from neurogenic detrusor overactivity.

Timeline

Start
2004-12
Primary completion
2005-06
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Propiverine Small molecule 15 mg
Subject Propiverine Small molecule 45 mg

Indications